Resumen

Background: Levodopa-induced dyskinesia is one of the main complications and limitations of the treatment of patients with Parkinson’s disease. Objective: To determine the incidence and risk factors involved in the development of dyskinesias in a retrospective cohort of Mexican patients with Parkinson’s disease. Material and methods: We reviewed a total of 601 cases of Parkinson’s disease patients treated at the National Institute of Neurology and Neurosurgery in the period between January 1990 and June 2010; 482 of them had history of exposure to levodopa. Results: The follow-up was equivalent to 4,392 person-years. 154 patients had dyskinesias at some point in the evolution of the disease. The person-time incidence was 35 cases per 1,000 person-years. The onset of motor symptoms before 50 years of age and levodopa doses ≥ 600 mg of levodopa were the main risk factors for early development of dyskinesia (HR of 1.01 [95% CI 1.0 to 1.01, p = 0.001] and HR 1.10 [95% CI 1.04 to 1.23, p = 0.04], respectively]. Conclusion: The main determinants of dyskinesias were present early age of onset of motor symptoms and the dose of levodopa. Knowledge of these factors will improve the management planning.

Palabras clave: Parkinson’s disease dyskinesia levodopa incidence Mexican.

2014-11-06   |   459 visitas   |   Evalua este artículo 0 valoraciones

Vol. 64 Núm.3. Mayo-Junio 2012 Pags. 220-226 Rev Invest Clin 2012; 64(3-ENGLISH)